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Abstract
Summary—Weekly bisphosphonates are the primary agents used to treat osteoporosis. Although
these agents are generally well tolerated, serious gastrointestinal adverse events, including
hospitalization for gastrointestinal bleed, may arise. We compared the gastrointestinal safety
between weekly alendronate and weekly risedronate and found no important difference between
new users of these agents.
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Introduction—Weekly bisphosphonates are the primary agents prescribed for osteoporosis. We
examined the comparative gastrointestinal safety between weekly bisphosphonates.
Methods—We studied new users of weekly alendronate and weekly risedronate from June 2002
to August 2005 among enrollees in a state-wide pharmaceutical benefit program for seniors. Our
primary outcome was hospitalization for upper gastrointestinal bleed. Secondary outcomes
included outpatient diagnoses for upper gastrointestinal disease, symptoms, endoscopic
procedures, use of gastroprotective agents, and switching between therapies. We used Cox
proportional hazard models to compare outcomes between agents within 120 days of treatment
initiation, adjusting for propensity score quintiles. We also examined composite safety outcomes
and stratified results by age and prior gastrointestinal history.
Results—A total of 10,420 new users were studied, mean age=79 years (SD, 6.9), and 95%
women. We observed 31 hospitalizations for upper gastrointestinal bleed (0.91 per 100 person-
years) within 120 days of treatment initiation. Adjusting for covariates, there was no difference in
hospitalization for upper gastrointestinal bleed among those treated with risedronate compared
with alendronate (HR, 1.12; 95%CI, 0.55 to 2.28). Risedronate switching rates were lower;
otherwise, no differences were observed for secondary or composite outcomes.
Conclusions—We found no important difference in gastrointestinal safety between weekly oral
bisphosphonates.
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Introduction
Weekly oral bisphosphonates are currently the primary pharmaceutical agents used for
managing osteoporosis [1–4]. These agents are generally well tolerated with adverse events
largely related to upper gastrointestinal complaints, erosions, and ulcers [5]. Prior evidence
suggests that risedronate may have a more favorable gastrointestinal profile. Randomized
controlled endoscopic studies show fewer gastric ulcers among daily risedronate users
within 14 days of treatment initiation compared with daily alendronate recipients [6, 7].
Observational studies also identify fewer gastrointestinal events within 4 months of
treatment initiation among new recipients of risedronate versus alendronate [8, 9]. However,
more recent data from a randomized controlled trial found no difference in gastrointestinal
tolerability or adverse events causing discontinuation when comparing the efficacy and
tolerability of weekly dosing of these agents [10, 11]. This finding has biological plausibility
as a weekly dosing interval may provide time for early esophageal lesions to heal between
exposures [12]. Nonetheless, due to exclusion criteria, results from this trial may not be
widely applicable to the general population of patients treated with these agents [13].
Clinicians may therefore struggle with determining the best option for osteoporosis
treatment from a safety standpoint. To examine the comparative gastrointestinal safety of
weekly risedronate versus weekly alendronate, we performed an observational study of new
recipients of these agents eligible for a state-wide pharmaceutical benefit program. We




The study population was identified from health care utilization data for enrollees in the
Pennsylvania Pharmaceutical Assistance Contract for the Elderly (PACE). This state-run
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program provides drug coverage without restriction for low-income residents aged 65 or
more years with annual household income too high for Medicaid. Study eligibility was
limited to patients with one or more claims in both Medicare and PACE in each of the three
6-month intervals preceding the index prescription. This was to ensure a minimum of 12
months of enrollment without any use of the study drugs prior to defining new use. We
assembled a cohort of new recipients of weekly bisphosphonate therapy approved for
osteoporosis treatment restricted to the period when both agents were available and
dispensed in our cohort. Our cohort therefore included new recipients (no prescription filled
for any oral bisphosphonate approved for osteoporosis management within the previous 365
days) of weekly alendronate (70 mg) and weekly risedronate (35 mg) between June 16, 2002
(date risedronate first dispensed in our cohort) and August 31, 2005 (Fig. 1). We excluded
residents of nursing homes (where prescription data may not be complete), patients with a
Medicare claim for Paget disease (International Classification of Diseases, Ninth Revision,
Clinical Modification code 731.0), use of alendronate solution, and those with a history of
any other bisphosphonate use (e.g., etidronate, which is not approved for osteoporosis
management in the United States) within the year prior to index prescription. Our data
included all PACE beneficiaries that met eligibility criteria. At the time of analysis, we had
complete Medicare data through to December 31, 2005.
Outcomes
Our primary outcome was hospitalization for upper gastrointestinal bleed (hemorrhage or
perforation) defined by primary discharge diagnosis in Medicare claims using previously
validated criteria [14, 15]. Secondary outcomes included outpatient diagnosis for
gastrointestinal diseases (peptic ulcer disease, gastrointestinal reflux disease, or gastritis),
outpatient diagnosis for gastrointestinal symptoms (abdominal pain, dyspepsia, heartburn,
nausea, or vomiting), upper gastrointestinal endoscopy, and use of gastroprotective agents
(H2-receptor antagonists, proton pump inhibitors, misoprostol, or sucrulfate). Finally, we
examined switching between agents as a general marker of side effects associated with
initial therapy. Table 3 of the Appendix provides specific diagnostic and procedural codes
used in our study.
Covariates
Patient demographics were determined at the time of treatment initiation and other variables
by medical and pharmacy claims within the year prior to treatment initiation. Covariates
included factors plausibly related to upper gastrointestinal morbidity [16–25] such as
demographics (age, sex, race), upper gastrointestinal-related (e.g., in- and outpatient
gastrointestinal disease, varices, Mallory–Weiss syndrome), osteoporosis-related diagnoses
(e.g., kyphosis, osteoporosis, vertebral fracture), comorbidities (e.g., alcohol abuse,
coagulation defects, chronic liver disease, Crohn’s disease, gastroenteritis, depression,
overweight/obesity), drug use (e.g., antiplatelet/antithrombotic, gastroprotective agents,
glucocorticoids, selective Cox-2 inhibitors, other nonsteroidal antiinflammatory, number of
generics), and prior hospitalization. We also included calendar time (month and year) of the
index prescription to adjust for potential secular trends in prescribing or coding. Table 4 of
the Appendix lists all variables, definitions, and coding. If a record of a specific diagnosis,
procedure, or prescription was lacking, patients were coded as not having these
characteristics. As a result of this coding rule, there were no participants for whom exposure,
confounder, or outcome information was missing.
Statistical analysis
Descriptive characteristics and covariates were summarized by user group. We used Cox
proportional hazard models to compare the rates of occurrence of each outcome between
weekly risedronate and weekly alendronate, censoring only on the date of death or end of
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follow-up (120 days following treatment initiation). We therefore followed surviving
patients throughout the 120-day period of follow-up, regardless of whether or not
prescription refills suggested continued exposure. We tested proportional hazards
assumptions by including an interaction term between exposure and the log of time, finding
no violations over the 120-day period of follow-up.
Alendronate was selected as the reference category in all Cox proportional hazard models.
We developed exposure propensity scores for risedronate prescribing using logistic
regression to adjust for confounding. Propensity score methods of adjustment are
comparable to conventional multiple variable adjustment [26]. However, propensity score
methods of adjustment reduce the number of covariates included in the outcome model and
are thus advantageous when studying rare outcomes [27, 28]. We also restricted the adjusted
analyses to recipients with overlapping propensity scores; minimum propensity scores equal
to the lowest value observed among risedronate recipients (“exposed”) and maximum value
equal to that observed among alendronate recipients (“unexposed”). Risedronate propensity
score quintiles (four dummy variables) were used to adjust for confounding in Cox
proportional hazard models.
In sensitivity analyses, we examined two composite outcomes: (1) any upper gastrointestinal
diagnosis or procedure and (2) any gastrointestinal outcome considered, as well as modified
our outcome coding for upper gastrointestinal procedure by restricting it to the most
commonly identified codes in our cohort. In addition, we completed analyses stratified by
age, defined by the median age of our cohort (less than or equal to median age versus greater
than median age) and history of gastrointestinal events (gastrointestinal neoplasm or any
upper gastrointestinal diagnosis, symptom, or procedure; versus none) within the year prior
to treatment initiation. Analyses were completed using SAS 9.1 (SAS, Cary, NC, USA).
In a secondary analysis, we additionally censored patients on the first day of switching
agents, losing drug plan eligibility, entering a nursing home, or discontinuing drug therapy
(last date covered by drug plus 15 days, allowing for 30-day gaps between prescriptions)
[13]. Finally, we examined the extent of residual confounding necessary to account for a
null finding if in fact differences in hospitalization for gastrointestinal bleed exist between
agents [29]. In applying the “array approach” (Microsoft Excel file available at
www.drugepi.org) [29], we allowed the relative risk between the possible unmeasured
confounder and gastrointestinal bleed to vary from 1 to 5.5 and the prevalence of this
unmeasured confounder among risedronate recipients (exposed) to vary from 0% to 50%.
We produced separate figures to compare results assuming that the prevalence among
alendronate recipients (unexposed) was 10%, 20%, or 40%. We were specifically interested
in examining the extent of confounding if the true relative risk was 0.70 (based on a
previously reported estimate for a broad gastrointestinal outcome where the hazard ratio was
1.4 for alendronate compared to risedronate) [9].
The Partners HealthCare Institutional Review Board approved this project. Data Use
Agreements are in place from PACE and the Centers for Medicare and Medicaid Services.
Results
Study cohort
Of 12,042 new recipients of weekly bisphosphonates identified, 1,622 were excluded (1,196
nursing home residents, 364 treated before the first dispensing of risedronate in our cohort,
63 dispensed alendronate solution, 19 had other previous bisphosphonate use, and 33 Paget
disease). We studied the remaining 10,420 new recipients (Table 1). The mean age of our
cohort was 78.7 years (SD=6.9, range 65–101, median=79), 95% women and 95%
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Caucasian. There was little evidence of potential confounding between alendronate and
risedronate recipients, with each group being of similar age and having similar disease risk
profiles (prevalence of comorbidities). However, slightly more risedronate recipients had a
background history of gastrointestinal events (38% versus 35%) and had been treated with
gastroprotective agents (38% versus 34%). In contrast, more alendronate recipients (23%
versus 20%) had been hospitalized in the year prior to their index prescription. These
differences disappeared within risedronate propensity score quintiles, with a mean difference
between quintiles of 0.1% for gastrointestinal event history, 0.3% for gastroprotective
agents, and 0.2% for previous hospitalization (Table 5 of the Appendix).
Comparative gastrointestinal safety
We observed 31 hospitalizations for upper gastrointestinal bleed (0.91 per 100 person-years)
within 120 days of treatment initiation. We found no difference between the rates of
hospitalization for upper gastrointestinal bleed (HR, 1.12; 95%CI, 0.55 to 2.28) or any other
outcome considered in our primary analyses (Table 2). Although the number of events was
too small to examine differences in hospitalization by gastrointestinal history or among
those aged younger than 80 years, we found no difference between agents among those aged
80 or more years (2.58 bleeds per 100 person-years of follow-up; HR, 0.97; 95%CI, 0.45 to
2.08).
Using the array approach, it is unlikely that our null finding is due to residual confounding.
For example, if an unmeasured confounder has a strong relationship with our outcome
(relative risk of 5.0) and its prevalence is 20% among alendronate recipients, then its
prevalence would need to be twofold (over 40%) higher among risedronate recipients to
bring the “fully adjusted” estimate from the observed value of 1.12 to 0.70 (Fig. 3 of the
Appendix). Similarly, if the prevalence of the confounder was only 10% (instead of 20% as
described in the figure) among alendronate recipients, the prevalence of the confounder
would need to be more than twofold higher (22% or more) to bring an observed estimate of
0.95 (e.g., observed for outpatient visits for gastrointestinal disease in our study) to a fully
adjusted estimate of 0.7 (figure not shown).
Overall, we document no large differences between agents for secondary or composite
outcomes, except that risedronate users had lower switching rates (Fig. 2). Lower switching
rates among risedronate versus alendronate users was also observed in the secondary (“on-
treatment”) analysis. In the main on-treatment analysis (hospitalization for gastrointestinal
bleed), 59% were censored at the end of the 120 days of observation, and 39% were
censored due to stopping treatment. Patients persisted with therapy for a mean of 87.6 days
(SD=41.2), and there was no difference in persistence with therapy between agents
(P=0.17). Among those with known history of gastrointestinal events, we found that rates
for upper gastrointestinal endoscopic procedures were lower among risedronate (HR, 0.70;
95% CI, 0.49 to 0.99) compared with alendronate recipients. However, when endoscopies
and switching between therapies were combined with upper gastrointestinal diagnoses and
symptoms within 120 days after treatment initiation as the outcome, we found no large
difference between agents (HR, 0.98; 95%CI, 0.92 to 1.04). Similar results were found when
we examined endoscopies using the more restrictive coding (data not shown).
Discussion
A recent systematic review concluded that there is no difference in the rates of upper
gastrointestinal events between alendronate or risedronate and placebo [30]. Our findings
further suggest that there is no important difference in the gastrointestinal safety between
weekly risedronate and weekly alendronate tablets. We did an English language MEDLINE
search through April 2008 to identify any large comparative observational studies and
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relevant head-to-head trials examining gastrointestinal safety between weekly oral
bisphosphonates. Prior observational studies comparing gastrointestinal safety of these
agents document fewer gastrointestinal events with daily risedronate compared with daily or
weekly alendronate [8, 9]. Although we found no difference in gastrointestinal safety,
identified by upper gastrointestinal bleed, diagnosis, or symptom, we did identify that fewer
risedronate users compared to alendronate users switched between therapies. The clinical
significance of this finding, however, is unclear because we found no difference in
persistence with therapy or in gastrointestinal diagnoses or symptoms documented between
agents. The decision to switch between therapies indicated for the same condition is made
based on the prescriber’s perceptions about the general adverse events caused by each agent.
Risedronate was heavily marketed as having a safer gastrointestinal risk profile compared to
alendronate. Caution in interpretation regarding the clinical significance of switching
between agents in this observational study is thus warranted.
Our findings are consistent with results from the Fosamax Actonel Comparison Trial
(FACT) that found comparable gastrointestinal safety between weekly alendronate and
risedronate among 1,053 postmenopausal women (mean age= 64.5 years) with low bone
mineral density [10]. Randomized controlled trials such as the FACT establish drug efficacy
within defined patient populations, often not representative of those who may benefit from
pharmacotherapy or how the agents, are used in practice [31]. We studied a much larger and
older cohort of new bisphosphonate recipients, and our findings complement and
corroborate FACT results.
Although our study design may allow for wider generalizability compared to prior studies
[8–10], we are limited because our study relies entirely on claims data. Data not captured
within administrative claims may be associated with gastrointestinal outcomes. For example,
we lacked data on cigarette smoking [23], alcohol consumption, body mass index [18], and
the use of over-the-counter products such as nonsteroidal antiinflammatory agents or
gastroprotective medications. More risedronate recipients in our study had a background
history of gastrointestinal disease and had been prescribed a gastro-protective agent.
Channeling of patients with gastrointestinal disease to risedronate versus alendronate has
also been observed in a cohort of chronic glucocorticoid users [32]. If risedronate recipients
in our study also had more risk factors for upper gastrointestinal disease not measured by
our data, our null findings may be attributed to residual confounding. However, using the
“array approach” for sensitivity analysis [29], a strong confounder (e.g., relative risk of 5.0)
and large imbalances between exposure groups (e.g., 20% alendronate versus 40%
risedronate) would be required to account for our null findings. Instead, we document very
small differences in background history of gastrointestinal disease (about 3%) using data
measured in healthcare utilization data. We therefore do not believe that the differences
between unmeasured factors such as alcohol consumption, cigarette smoking, or body mass
index would fully explain our findings of comparable gastrointestinal safety.
We found a consistent lack of difference in risk between agents among those with no
gastrointestinal history. However, among the smaller cohort of patients with history of
gastrointestinal events, risedronate recipients had lower rates of endoscopy. Although the
definition of our primary outcome (hospitalization for upper gastrointestinal bleed) has been
validated, we cannot rule out the possibility that outpatient diagnoses and symptoms
identified in claims data reflect care to “rule-out” upper gastrointestinal disease or follow-up
visits for preexisting conditions. It is thus difficult to make strong conclusions based on this
secondary endpoint alone. It could be that endoscopy represents more severe gastrointestinal
side effects, or it could represent a differential in practice style between physicians who
prescribe alendronate versus risedronate. Indeed, after combining endoscopy with outpatient
diagnoses for upper gastrointestinal disease or symptoms, we observed no difference
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between agents. Therefore, the clinical importance of differences in the rates of upper
gastrointestinal endoscopy identified by our study is unclear and caution in interpretation is
advised.
In addition to those already mentioned, four limitations are worth noting. First, by studying a
cohort of frail older adults from Pennsylvania, our results may not be general-izable to all
users of these agents, such as younger patients with chronic glucocorticoid treatment.
However, given that oral bisphosphonates are largely prescribed to treat primary
osteoporosis, we believe our study population to be a significant strength. We were able to
study a large cohort of older adults with complete drug coverage without restrictions
(alendronate and risedronate are fully covered with the same co-payment), and older frail
adults are at the highest risk for gastrointestinal disease [19].
Second, our study database only contained claims data to determine gastrointestinal
outcomes and may thus have misclassified some events. Prior studies have found that
gastrointestinal adverse events are one of the main reasons for discontinuing bisphosphonate
treatment for osteoporosis [33–36]. In our secondary (on-treatment) analysis, we document
that 39% were censored due to lack of persistence with treatment and another 1% switched
between agents. Although there were no differences in persistence or reasons for censoring
between agents, we may have underestimated the extent of gastrointestinal side effects
resulting from bisphosphonate treatment. For these reasons, we completed our primary
analyses using an “intention-to-treat scenario” and followed surviving patients for 120 days.
This analytic approach allows for a time lag between when a patient’s symptoms appear
(may stop taking medication) and presentation in a physician’s office with an upper
gastrointestinal complaint (requires time to book an appointment with a physician or to be
referred for endoscopy). We also focused on hospitalization for upper gastrointestinal bleed
using previously validated criteria [14, 15] as our primary outcome, and there is no reason to
believe that there would be differential misclassification in hospitalizations between
bisphosphonate therapies.
Third, our study is limited by statistical power due to few events observed for our primary
outcome (hospitalization for gastrointestinal bleed). One method to increase the number of
events under study would be to lengthen the period of observation beyond 120 days.
However, prior research has documented that upper gastrointestinal problems from oral
bisphosphonate therapy occur early in the time course of treatment [6, 7], and thus, 120 days
is an appropriate risk window of observation. Extending the length of observation could also
introduce information bias such as depletion of susceptibles [37]. Similarly, we were
concerned about the potential for informative censoring using an on-treatment analysis,
whereby patients experiencing early gastrointestinal discomfort stop taking their
bisphosphonate and would thus be censored from analysis before a signal is detected in
claims data.
Finally, we were unable to examine the comparative gastrointestinal safety of newer oral
bisphosphonate formulations. Ibandronate received FDA approval for osteoporosis treatment
using monthly dosing in March 2005. The prolonged dose-free interval may result in fewer
gastrointestinal events [12], but this remains to be documented by comparison with weekly
bisphosphonates in prospective studies. Risedronate also received FDA approval in April
2007 for monthly dosing (75 mg tablet on two consecutive days) to treat postmenopausal
osteoporosis. Future studies that examine the comparative gastrointestinal safety of oral
bisphosphonates are of interest.
In conclusion, we found no important difference in upper gastrointestinal safety between
weekly alendronate and weekly risedronate. Future studies may help to further identify if
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differences in gastrointestinal safety exist between oral bisphosphonates, particularly by
dosing interval (e.g., weekly versus monthly) and among patients with different risk profiles
(e.g., younger age and gastrointestinal risk).
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Study outcome coding (diagnoses and procedures)
Variable Definition
Primary outcomea
 Hospitalization for upper gastrointestinal bleed
(hemorrhage or perforation)
Primary discharge diagnosis of ICD-9-CM codes 531.0x, 531.1x,
531.2x, 531.4x, 531.5x, 531.6x, 532.0x, 532.1x, 532.2x, 532.4x,
532.5x, 532.6x, 533.0x, 533.1x, 533.2x, 533.4x, 533.5x, 533.6x,
578.0x, 578.1x, 578.9x
Secondary outcomesb
 1 Outpatient diagnosis for gastrointestinal
disease (peptic ulcer disease, gastrointestinal reflux
disease, or gastritis)
ICD-9-CM codes 530.1x, 530.2x, 530.3x, 530.4x, 530.8, 530.81,
530.82, 530.89, 530.9x, 531.xx, 532. xx, 533.xx, 535.0x, 535.4x,
535.5x, 535.6x
 2 Outpatient diagnosis for gastrointestinal
symptom (abdominal pain, dyspepsia, heartburn,
nausea, or vomiting)
ICD-9-CM codes 536.2x, 536.8x, 536.9x, 537.89, 537.9x,
578.xx, 787, 787.0x, 787.1x, 787.2x, 787.3x, 789, 789.0x
 3 Upper gastrointestinal endoscopy ICD-9-CM codes 45.13, 45.14, 45.16, 44.43 and CPT-4 codes
43234–43259
 4 Use gastroprotective agent Any pharmacy claim for H2- receptor antagonists, proton pump
inhibitors, misoprostol, or sucrulfate
 5 Switched between therapies First date filled prescription for the other agent
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 6 Any upper gastrointestinal diagnosis or
procedure
Primary outcome and/or secondary outcome nos. 1–3
 7 Any gastrointestinal diagnostic outcome or
procedure or gastroprotective treatment
Any of the above
CPT-4 Current Procedural Terminology, 4th edition, ICD-9-CM International Classification of Diseases, Ninth Revision,
Clinical Modification
a
Validation studies that compared claims data to hospital medical charts in Canada [14] and Spain [15] have found that
over 90% of patients with one of these codes as their primary hospital discharge diagnosis were indeed hospitalized for
upper gastrointestinal bleed
b
Although we are unaware of validation data for outpatient diagnostic codes, the positive predictive value of using ICD-9-
CM procedural codes for upper gastrointestinal endoscopy has been reported to be over 97% [38]. We supplemented these
ICD-9-CM procedural codes with CPT-4 codes to improve the sensitivity of our estimates [8]. Of those identified as having
had an upper gastrointestinal endoscopy in our study (N=224), 5% had ICD-9-CM codes only, 41% had CPT-4 codes only,
and 54% had both types of codes. In a sensitivity analysis, we restricted coding to the most commonly identified codes
(CPT-4 codes 43235, 43239; N=180)
Table 4
Definition and coding of variables included in logistic regression model used to create
propensity scores
Variable Definition Coding
Medicare enrolment information at time of index prescription
Age Age in years Categorical, one category for
each age, except grouping
ages 96+ into a single
reference group (31
dummies)
Male sex Male sex Dichotomous (yes/no)
Race Caucasian race Dichotomous (yes/no)
Date Month/year of index prescription Categorical (month/year),
one category for each month/
year (38 dummies)
Medicare claims within 365 days prior to index drug prescription
Hospitalization Any Dichotomous (yes/no)
Comorbidity score Charlson comorbidity score [39, 40] Ordinal (quartiles, 3
dummies)
Upper gastrointestinal (GI)
Inpatient GI diagnosis (ulcer or
bleed)
Any hospital discharge diagnosis of ICD-9-CM
codes 531.xx-535.xx, 578.xx, 537.83
Dichotomous (yes/no)
Outpatient GI diagnosis ICD-9-CM codes 530.xx-535.xx Dichotomous (yes/no)
Outpatient GI disorder or
abdominal discomfort
ICD-9-CM codes 536.xx-538.xx, 787.xx,
789.xx, 793.4
Dichotomous (yes/no)
Upper GI endoscopy ICD-9-CM codes 45.13, 45.14, 45.16, 44.43
and CPT-4 codes 43234-43259
Dichotomous (yes/no)
Helicobacter pylori infection ICD-9-CM codes 041.86 Dichotomous (yes/no)
Varices or Mallory–Weiss
syndrome
ICD-9-CM codes 456.0x, 456.20,456.1x,
456.21,
Dichotomous (yes/no)




Osteoporosis ICD-9-CM codes 733.0x dichotomous (yes/no)
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Kyphosis ICD-9-CM codes 737.1x, 737.41, 737.3x dichotomous (yes/no)
Prior vertebral fracture Vertebral (ICD-9-CM codes 733.13, 805.xx) dichotomous (yes/no)




Alcohol abuse ICD-9-CM codes 303.xx, V11.3, 291.xx,
571.0x, 571.1x, 571.2x, 571.3x, 357.5x,
535.3x, 425.5x, 265.2x, E860.0x
Dichotomous (yes/no)
Chronic liver disease ICD-9-CM codes 571.4x, 571.6x, 571.8x,
571.9x, 573.xx, 070.xx
Dichotomous (yes/no)
Coagulation defects ICD-9-CM codes 286.xx Dichotomous (yes/no)
Crohn’s disease or gastroenteritis ICD-9-CM codes 555.xx, 556.xx, 558.xx Dichotomous (yes/no)
Depression ICD-9-CM codes 293.83, 296.2x. 296.3x,
298.0x, 300.4x, 309.0x, 309.1x, 309.28, 311.xx
Dichotomous (yes/no)
Diabetes mellitus ICD-9-CM codes 250.xx and recipient of
diabetic drug
Dichotomous (yes/no)
Heart failure ICD-9-CM codes 428.xx
Hypertension ICD-9-CM codes 416.0x, 401.xx, 402.xx Dichotomous (yes/no)
Liver disease ICD-9-CM codes 571.4x, 571.6x, 571.8x,
571.9x, 573.xx, 070.xx
Dichotomous (yes/no)
Non-GI, non- skin neoplasm ICD-9-CM codes 160.xx- 171.xx,
174.xx-208.xx, 212.xx-229.xx, 231.xx- 234.xx,
235.6x-239.xx
Dichotomous (yes/no)
Osteoarthritis ICD-9-CM codes 715.xx Dichotomous (yes/no)
Overweight or obese ICD-9-CM codes 278, 278.0x Dichotomous (yes/no)
Rheumatoid arthritis ICD-9-CM codes 714.xx Dichotomous (yes/no)
Pharmacy claims within 365 days prior to index drug prescription
Number of generics Count Ordinal (quintiles, 4
dummies)
Antiplatelet/antithrombotic Any pharmacy claim Dichotomous (yes/no)
Gastroprotective Any pharmacy claim Dichotomous (yes/no)
Glucocorticoids Any pharmacy claim Dichotomous (yes/no)
Selective Cox-2 inhibitor Any pharmacy claim Dichotomous (yes/no)
Other NSAID Any pharmacy claim Dichotomous (yes/no)
SSRI Any pharmacy claim Dichotomous (yes/no)
Non-SSRI antipsychotic Any pharmacy claim Dichotomous (yes/no)
COX-2 cyclooxygenase-2, GI gastrointestinal, ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical
Modification, NSAID nonsteroidal antiinflammatory drug, SSRI selective serotonin reuptake inhibitors
Table 5
Cohort characteristics within propensity score quintiles for risedronate prescribing by drug
received, overlapping propensity scores (N=10,416)
Covariate Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
ALD RSD ALD RSD ALD RSD ALD RSD ALD RSD
No. 1,400 683 1,244 839 1,152 932 1,091 992 929 1,154
Mean age, years 79.4 79.5 78.3 77.8 78.4 78.1 78.4 78.6 79.0 79.3
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Covariate Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
ALD RSD ALD RSD ALD RSD ALD RSD ALD RSD
Men, % 11.9 10.5 5.5 5.1 3.1 3.2 1.9 2.2 0.8 1.5
White, % 88.6 88.3 94.1 93.8 95.9 97.0 99.0 98.2 98.2 99.0
Year of index prescription, %
 2002 39.5 38.2 21.9 22.6 15.2 14.7 9.6 9.7 3.7 3.1
 2003 21.0 20.6 27.7 28.5 30.0 30.8 34.6 32.2 35.4 36.9
 2004 11.0 12.3 21.7 18.8 29.5 28.5 36.2 39.0 50.2 51.0
 2005 28.5 28.8 28.8 30.0 25.3 26.0 19.5 19.2 10.8 8.9
Hospitalizations in previous year,
%
37.9 40.6 24.6 22.5 21.4 18.8 13.9 15.5 12.6 11.9
Gastrointestinal-related comorbidities, %
 Hospitalization for peptic ulcer
disease or bleed
0.9 0.7 0.5 0.4 0.8 0.6 0.7 0.5 0.4 1.0
 Outpatient GI diagnosis 10.9 12.3 13.3 12.8 17.5 16.1 22.6 22.9 36.2 38.0
 Outpatient disease or
discomfort
24.6 24.3 23.6 21.9 21.4 20.6 20.9 22.2 25.5 26.9
 Upper GI endoscopy 6.0 5.0 4.7 3.7 4.2 4.7 4.2 5.4 5.1 5.1
 Helicobacter pylori infection 0.5 0.6 0.5 0.0 0.2 0.4 0.1 0.1 0.0 0.1
 Varices or Mallory–Weiss
syndrome
0.1 0.0 0.0 0.1 0.1 0.1 0.1 0.0 0.2 0.3
 GI neoplasm 3.8 3.1 5.9 3.3 5.1 6.4 7.0 7.6 10.1 11.7
 Any GI event (any of above) 30.5 31.2 30.9 29.2 32.3 30.7 36.8 37.2 50.4 53.1
Osteoporosis-related, %
 Kyphosis 2.6 2.6 2.7 1.9 2.9 2.8 3.8 3.0 2.5 4.1
 Osteoporosis 36.6 41.0 41.7 43.5 51.6 46.7 57.8 59.1 70.9 70.5
 Prior vertebral fracture 11.9 13.6 8.5 8.0 7.6 6.5 7.0 6.4 5.3 5.5
 Prior hip or arm fracture 12.4 13.2 5.6 6.0 5.1 3.8 3.1 2.5 1.8 2.4
Other relevant comorbidities, %
 Alcohol abuse 0.9 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 Chronic liver disease 0.5 0.7 1.4 0.7 1.5 2.1 2.1 1.6 6.5 7.4
 Coagulation defects 4.6 4.4 2.9 2.9 1.7 2.1 2.2 2.1 2.2 2.0
 Crohn’s disease or
gastroenteritis
5.9 8.1 4.7 3.9 3.2 3.0 2.4 2.1 3.0 2.0
 Depression 9.9 10.7 8.0 7.9 8.5 8.3 11.5 10.0 12.8 14.0
 Diabetes mellitus 11.9 11.6 11.8 14.1 14.7 13.8 14.5 15.1 18.3 16.7
 Heart failure 16.8 19.2 12.1 10.8 12.8 12.3 14.6 12.0 15.1 17.1
Hypertension 68.8 70.0 62.8 65.9 66.9 66.3 69.7 71.5 75.2 69.9
 Non-GI, nonskin neoplasm 17.6 17.9 16.8 17.5 18.7 14.7 18.7 18.9 21.4 24.3
 Osteoarthritis 39.8 38.9 36.6 36.8 39.0 36.8 38.1 37.7 41.4 44.9
 Overweight or obese 3.1 3.2 2.5 2.0 3.0 3.2 1.9 1.5 1.3 1.6
 Rheumatoid arthritis 5.2 4.8 3.9 3.7 5.2 4.7 4.2 4.5 3.7 4.3
 Mean comorbidity score, No. 1.8 1.8 1.6 1.5 1.6 1.5 1.6 1.6 1.8 1.8
 Mean generics, No. 9.3 9.8 9.0 9.1 9.1 9.1 9.6 9.3 10.3 10.2
Pharmacy claims within 365 days prior to index osteoporosis drug prescription, %
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Covariate Quintile 1 Quintile 2 Quintile 3 Quintile 4 Quintile 5
ALD RSD ALD RSD ALD RSD ALD RSD ALD RSD
 Antiplatelet/antithrombotic 12.9 11.9 10.1 11.2 11.3 11.7 10.1 9.4 10.7 10.5
 Cardiovascular 77.6 77.5 77.3 78.1 77.6 77.9 79.9 80.9 80.9 78.9
 Gastroprotective 20.0 21.2 23.2 23.5 33.6 32.6 40.7 40.5 59.4 60.5
 Glucocorticoids 14.1 13.3 12.9 12.6 13.5 14.1 11.8 13.6 15.4 13.7
 Selective Cox-2 inhibitor 25.2 27.2 24.0 23.2 21.8 19.2 16.3 17.9 15.6 15.1
 Other NSAID 17.7 17.9 15.4 15.9 14.9 13.9 11.0 11.3 10.4 10.1
 SSRI 17.7 17.4 14.5 13.8 16.2 14.8 18.7 19.0 17.2 19.6
 Non-SSRI antipsychotic 4.0 6.4 5.5 6.4 8.8 6.1 9.8 10.6 19.8 19.1
COX-2 cyclooxygenase-2, GI gastrointestinal, NSAID nonsteroidal antiinflammatory drug, SSRI selective serotonin
reuptake inhibitors, ALD alendronate, RSD risedronate
Fig. 3.
Sensitivity analysis of residual confounding using the array approach for our primary
outcome (hospitalization for upper gastrointestinal bleed). To facilitate interpretation by the
reader, we have maintained the notation used in the explanatory article and Excel program
that we modified (available at www.drugepi.org) to produce this figure [29]. ARR apparent
exposure relative risk, i.e., the relative risk (hazard ratio) observed in the current study
(risedronate versus alendronate), fixed at 1.12. PC0 prevalence of counfounder among
unexposed (alendronate), fixed at 20% in this example. PC1 prevalence of confounder
among exposed (risedronate) group, varied from 0% to 50% in the figure. RRCD association
between confounder and disease outcome, varied from 1.0 to 5.5 in figure. RR fully adjusted
or “true” exposure relative risk. Blue line no confounding present, prevalence of confounder
same among alendronate and risedronate recipients
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Flow diagram of cohort assembly and inclusion into the main and subgroup analyses. Single
asterisk May meet more than one exclusion criterion. Double asterisk Study restricted to
when both agents were used in our cohort, defined by the first date risedronate was
dispensed in our cohort (June 16, 2002). Oral bisphosphonates were doses approved for the
prevention or treatment of osteoporosis (alendronate [5, 10, 35, 70 mg], risedronate [5 or 35
mg], ibandronate [150 mg]). Weekly oral bisphosphonates studied were alendronate (70 mg)
and risedronate (35 mg)
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Adjusted hazard ratio (HR) estimates and 95% confidence intervals within 120 days of
treatment initiation among new recipients of weekly risedronate versus weekly alendronate
(alendronate is the reference group). a Primary analysis stratified by age. b Primary analysis
stratified by gastrointestinal history. c Secondary (on-treatment) analysis, censoring patients
on the first day of switching agents, losing drug plan eligibility, entering a nursing home, or
discontinuing drug therapy (last date covered by drug plus 15 days, allowing for 30-day gaps
between prescriptions), or 120 days after treatment initiation. GIDX gastrointestinal disease
(outpatient diagnosis for peptic ulcer disease, gastrointestinal reflux disease, or gastritis).
GISX gastrointestinal symptoms (outpatient diagnosis for abdominal pain, dyspepsia,
heartburn, nausea, or vomiting). GIPX upper gastrointestinal endoscopy. DXSXPX any
gastrointestinal diagnostic outcome (including hospitalization for upper gastrointestinal
bleed) or procedure. GITX gastroprotective agent. SWITCH switched between therapies.
ANY any gastrointestinal diagnostic outcome or procedure, or gastroprotective treatment, or
switched between therapies
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Table 1
Characteristics of new recipients of weekly alendronate and weekly risedronate, June 2002–August 2005
Alendronate recipients (n=5,818) Risedronate recipients (n=4,602)
Mean age (SD), years 78.7 (6.8) 78.7 (6.9)
Mean generic drugs (SD), n 9.4 (5.4) 9.5 (5.5)
Median comorbidity score (25th,75th percentile), n 1 (0–3) 1 (0–3)
Median physician visits (25th,75th percentile), n 7 (3–12) 7 (4–12)
Male, % 5.2 4.0
Caucasian, % 94.7 95.9
Hospitalization within previous year, % 23.3 20.3
Gastrointestinal-related comorbidities, %
 Inpatient gastrointestinal diagnosis (ulcer or bleed) 0.7 0.7
 Outpatient gastrointestinal diagnosis 19.0 21.9
 Outpatient gastrointestinal disorder or discomfort 23.2 23.3
 Upper gastrointestinal endoscopy 4.9 4.8
 Helicobacter pylori infection 0.3 0.2
 Varices or Mallory–Weiss syndrome 0.1 0.1
 Gastrointestinal neoplasm 6.1 6.9
 Any of the above (gastrointestinal event history) 35.3 37.5
Osteoporosis-related diagnoses, %
 Kyphosis 2.9 3.0
 Osteoporosis 50.1 53.9
 Prior fracture—vertebral 8.3 7.5
 Prior hip or arm fracture 6.1 5.0
Other comorbidities, %
 Alcohol abuse 0.3 0.1
 Chronic liver disease 2.1 2.9
 Coagulation defects 2.8 2.6
 Crohn’s disease or gastroenteritis 4.0 3.5
 Depression 10.0 10.4
 Diabetes mellitus 13.9 14.6
 Heart failure 14.3 14.2
 Hypertension 68.3 68.8
 Nongastrointestinal, nonskin neoplasm 18.5 19.0
 Osteoarthritis 38.9 39.4
 Overweight or obese 2.4 2.2
 Rheumatoid arthritis 4.5 4.4
Medication use, %
 Antiplatelet/antithrombotic 11.1 10.8
 Cardiovascular 78.5 78.8
 Gastroprotective 33.6 38.0
 Glucocorticoids 13.5 13.5
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Alendronate recipients (n=5,818) Risedronate recipients (n=4,602)
 Selective Cox-2 inhibitor 21.1 19.8
 Other nonsteroidal antiinflammatory 14.2 13.3
 SSRI 16.8 17.1
 Non-SSRI antipsychotic 8.9 10.5
Characteristics identified by pharmacy (Pennsylvania Pharmaceutical Assistance Contract for the Elderly) and Medicare claims within the 12
months prior to treatment initiation. Diagnostic and procedural codes listed in Table 3 of the Appendix
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